Review paper

Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology

Volume: 145, Pages: 144 - 156
Published: Jan 1, 2015
Abstract
Recently two drugs, namely the antiandrogen MDV-3100 and the inhibitor of 17α-hydroxylase abiraterone have been accepted by the FDA for the treatment of castration-resistant prostate cancer (CRPC) with or without previous chemotherapy, with a prolongation of overall survival of 2.2–4.8 months. While medical (GnRH agonist) or surgical castration reduces the serum levels of testosterone by about 97%, an important concentration of testosterone and...
Paper Details
Title
Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology
Published Date
Jan 1, 2015
Volume
145
Pages
144 - 156
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.